MIRM
NASDAQMirum Pharmaceuticals Inc.
Price$93.46+0.25 (+0.27%)
01:45 PM07:45 PM
News · 26 weeks1130%
2025-12-142026-06-07
Mix5290d
- SEC Filings19(37%)
- Insider15(29%)
- Other12(23%)
- Earnings4(8%)
- Analyst2(4%)
Latest news
25 items- INSIDERPRESIDENT AND COO Radovich Peter exercised 16,988 shares at a strike of $19.19, increasing direct ownership by 42% to 57,260 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) and Incyte (NASDAQ:INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva ("FOP") will be presented at ENDO 2026, the Endocrine Society's annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604863826/en/
- INSIDERDirector Cardon Lon converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Peetz Christopher exercised 30,000 shares at a strike of $2.94 and sold $2,875,103 worth of shares (30,000 units at $95.84) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Walbert Timothy P converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Fischer Laurent converted options into 3,977 shares, increasing direct ownership by 59% to 10,727 units (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- INSIDERDirector Ramasastry Saira converted options into 3,977 shares and sold $397,700 worth of shares (3,977 units at $100.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- ANALYSTCitigroup initiated coverage on Mirum Pharmaceuticals with a new price targetCitigroup initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $145.00
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV), including in patients with advanced disease - Treatment with LIVMARLI® (maralixibat) demonstrates improved event-free survival in patients with progressive familial intrahepatic cholestasis (PFIC) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS s
- PRMirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 results demonstrate efficacy and safety of brelovitug for the treatment of chronic hepatitis delta virus (HDV) - Additional presentations highlight long-term outcomes and real-world experience with LIVMARLI® (maralixibat) in progressive familial intrahepatic cholestasis (PFIC) Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will present new data at the European Association for the Study of the Liver (EASL) International Liver Congress 2026,
- ANALYSTWolfe Research initiated coverage on Mirum Pharmaceuticals with a new price targetWolfe Research initiated coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $145.00
- INSIDERDirector Ramasastry Saira exercised 2,000 shares at a strike of $23.51 and sold $218,940 worth of shares (2,000 units at $109.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
- SECMirum Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- SECSEC Form 144 filed by Mirum Pharmaceuticals Inc.144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
- PRMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 22,950 shares of common stock and 31,300 restricted stock units ("RSUs") to 12 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $106.17 per share, which is equal to the closing price of Mirum's common stock on May 11
- PRMirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible NotesMirum Pharmaceuticals, Inc. ("Mirum") (NASDAQ:MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The issuance and sale of the notes are scheduled to settle on May 15, 2026, subject to customary closing conditions. Mirum also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date th
- PRMirum Pharmaceuticals Announces Proposed Convertible Senior Notes OfferingMirum Pharmaceuticals, Inc. ("Mirum") (NASDAQ:MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Mirum also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $90.0 million aggregate pri
- PRMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference: Tuesday, May 19, 2026 Company fireside chat starting at 3:30 p.m. ET 2026 RBC Capital Markets Global Healthcare Conference: Wednesday, May 20, 2026 Company fireside chat starting at 1:35 p.m. ET The fireside chats will be webcast live and can be accessed by visiting the Investors section of Mirum's corporate website. The archived webcasts will be available for replay. About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ:MIRM) is a leading rare
- SECSEC Form 10-Q filed by Mirum Pharmaceuticals Inc.10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- SECMirum Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
- PRMirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update- Q1 2026 net product sales of $159.9 million - 2026 net product sales guidance increased to $660 to $680 million - Volixibat VISTAS Phase 2b study met primary endpoint - Brelovitug Phase 2b portion of AZURE-1 study met primary endpoint - In-licensed exclusive worldwide rights to zilurgisertib (ALK2 inhibitor) for FOP; FDA Priority Review granted with September 26, 2026 PDUFA date - Conference call to provide business updates today, May 6 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today reported financial results for the first quarter 2026 and provided a business update. "2026 is off to an excellent start, driven b
- SECSEC Form 8-K filed by Mirum Pharmaceuticals Inc.8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
MIRM FAQ
7 questionsWhat does Mirum Pharmaceuticals Inc. do?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was...Where does MIRM stock trade?
Mirum Pharmaceuticals Inc. (MIRM) is listed on NASDAQ.What sector and industry is MIRM in?
Mirum Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Mirum Pharmaceuticals Inc. go public?
Mirum Pharmaceuticals Inc. (MIRM) completed its IPO in 2019.What are analysts saying about MIRM?
Mirum Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-06-02. Recent price targets cluster around $4800.00.What companies are similar to MIRM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MIRM side-by-side with any of them on Quantisnow.How can I track MIRM on Quantisnow?
Quantisnow aggregates Mirum Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIRM to receive live email and push alerts on every new disclosure.